Conduit Pharmaceuticals INC DEF 14A proxy statements

CDT Equity Inc. announced its 2026 virtual annual meeting of stockholders, detailing proposals including director elections, auditor ratification, reverse stock splits, and share issuances.

CDT Equity Inc. is seeking stockholder approval for several critical proposals, including significant share issuances, an equity line of credit, a reverse stock split, an increase in authorized shares, and redomestication to the Cayman Islands.

Conduit Pharmaceuticals Inc. announced its 2025 virtual annual meeting to elect directors, ratify auditors, and approve a significant increase in its stock incentive plan, while detailing recent management changes, related party transactions, and a new licensing agreement with AstraZeneca.

Conduit Pharmaceuticals is asking stockholders to approve a reverse stock split, ranging from 1-for-2 to 1-for-100 (and up to 1-for-250 in aggregate), to potentially maintain its Nasdaq listing and attract investors.

Conduit Pharmaceuticals is holding a special virtual meeting on January 9, 2025, to seek stockholder approval for the issuance of common stock related to warrant exercises and the conversion of promissory notes.

Conduit Pharmaceuticals files a supplement to its proxy statement to correct errors regarding director independence and audit committee composition, aiming to comply with Nasdaq listing standards by December 18, 2024.

Conduit Pharmaceuticals Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Conduit Pharmaceuticals is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Global Market and potentially increase investor interest.